CA2132544C - Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy - Google Patents

Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy Download PDF

Info

Publication number
CA2132544C
CA2132544C CA002132544A CA2132544A CA2132544C CA 2132544 C CA2132544 C CA 2132544C CA 002132544 A CA002132544 A CA 002132544A CA 2132544 A CA2132544 A CA 2132544A CA 2132544 C CA2132544 C CA 2132544C
Authority
CA
Canada
Prior art keywords
tetrazol
biphenyl
methyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002132544A
Other languages
English (en)
French (fr)
Other versions
CA2132544A1 (en
Inventor
Frank Carey
Alexander Anthony Oldham
Norman Eugene Cameron
Mary Anne Cotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929208116A external-priority patent/GB9208116D0/en
Priority claimed from GB929211289A external-priority patent/GB9211289D0/en
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of CA2132544A1 publication Critical patent/CA2132544A1/en
Application granted granted Critical
Publication of CA2132544C publication Critical patent/CA2132544C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002132544A 1992-04-13 1993-04-07 Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy Expired - Fee Related CA2132544C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929208116A GB9208116D0 (en) 1992-04-13 1992-04-13 Therapeutic agents
GB9208116.5 1992-04-13
GB929211289A GB9211289D0 (en) 1992-05-28 1992-05-28 Heterocyclic therapeutic agents
GB9211289.5 1992-05-28
PCT/GB1993/000732 WO1993020816A1 (en) 1992-04-13 1993-04-07 Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy

Publications (2)

Publication Number Publication Date
CA2132544A1 CA2132544A1 (en) 1993-10-28
CA2132544C true CA2132544C (en) 2005-10-18

Family

ID=26300705

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002132544A Expired - Fee Related CA2132544C (en) 1992-04-13 1993-04-07 Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy

Country Status (14)

Country Link
EP (2) EP0636027B1 (enExample)
JP (1) JPH07505646A (enExample)
KR (1) KR100292396B1 (enExample)
AT (1) ATE181830T1 (enExample)
AU (1) AU675935B2 (enExample)
CA (1) CA2132544C (enExample)
DE (1) DE69325574T2 (enExample)
DK (1) DK0636027T3 (enExample)
ES (1) ES2135472T3 (enExample)
GR (1) GR3031261T3 (enExample)
HU (1) HUT71331A (enExample)
NO (1) NO313935B1 (enExample)
NZ (1) NZ251741A (enExample)
WO (1) WO1993020816A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232663C (en) * 1995-10-06 2008-04-08 Novartis Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
AU1791497A (en) 1996-02-29 1997-09-16 Novartis Ag At1 receptor antagonist for the stimulation of apoptosis
SK283348B6 (sk) * 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CZ297795B6 (cs) 1998-12-23 2007-03-28 Novartis Ag Tablety obsahující valsartan
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
EP2650011A1 (en) 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
CN102885818B (zh) 2006-03-20 2016-05-04 诺华股份有限公司 治疗或预防炎性痛的方法
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN107744519A (zh) 2010-01-19 2018-03-02 诺华股份有限公司 改良神经传导速度的方法和组合物
KR20250007040A (ko) 2017-07-07 2025-01-13 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2025125409A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234854A (en) * 1989-08-11 1993-02-25 Ici Plc Quinoline derivatives, preparation, intermediates and pharmaceutical compositions thereof
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
EP0528762B1 (de) * 1991-08-15 1997-05-07 Novartis AG N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten

Also Published As

Publication number Publication date
AU3958993A (en) 1993-11-18
ES2135472T3 (es) 1999-11-01
ATE181830T1 (de) 1999-07-15
DE69325574T2 (de) 2000-03-16
KR100292396B1 (enExample) 2001-09-17
AU675935B2 (en) 1997-02-27
WO1993020816A1 (en) 1993-10-28
NO943846L (no) 1994-10-12
EP0872235A1 (en) 1998-10-21
DK0636027T3 (da) 2000-01-31
NZ251741A (en) 1997-06-24
NO943846D0 (no) 1994-10-12
GR3031261T3 (en) 1999-12-31
HUT71331A (en) 1995-11-28
EP0636027A1 (en) 1995-02-01
DE69325574D1 (de) 1999-08-12
CA2132544A1 (en) 1993-10-28
NO313935B1 (no) 2002-12-30
HU9402932D0 (en) 1995-02-28
JPH07505646A (ja) 1995-06-22
EP0636027B1 (en) 1999-07-07

Similar Documents

Publication Publication Date Title
CA2132544C (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
EP2524693B1 (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
TWI415605B (zh) 用於預防或治療貓之全身性疾病之血管緊張素ii受體拮抗劑
AU745759B2 (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
DE68903092T2 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
US6448280B1 (en) Angiotensin II antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
EP0561977B1 (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
US7064141B1 (en) Method for preventing, treating or inhibiting development of simple retinopathy and preproliferative retinopathy
EP0660713B1 (en) Use of angiotensin ii antagonists in the treatment of left ventricular hypertrophy
CA2373881A1 (en) Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications
TWI289060B (en) Pharmaceutical composition for improving the recovery of post-stroke patients
JPH0532635A (ja) ヒスタミン誘導体の治療への応用と、新規なヒスタミン誘導体と、この誘導体の医薬としての使用
JP2003535897A (ja) アンギオテンシンｉｉアンタゴニストの新規使用法
SK7832000A3 (en) New use of local anaesthetics against vascular headaches
SK159597A3 (en) Use of alendronate for the prevention of osteoporosis
EP1391203A1 (en) Antitumor agents
WO2004105756A2 (en) Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
JP2003522792A (ja) 薬剤調製用化合物の用途
DE4020133A1 (de) Pharmazeutische zusammensetzung zur verwendung gegen bluthochdruck und chronische herzinsuffizienz
KR20010013014A (ko) 고립성 수축기 고혈압증의 치료 방법
NZ299704A (en) Use of a beta-lactam cholesterol absorption inhibitor and a cholesterol biosynthesis inhibitor (eg lovastatin) in preparation of pharmaceutical compositions for treatment of plasma cholesterol levels
JPH09136843A (ja) 血圧上昇薬
HK1173084A (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
DE10123447A1 (de) Cilansetron enthaltende Arzneimittel zur Behandlung nicht-obstipativer männlicher IBS-Patienten

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed